Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

The effect of antidepressants on patient-reported health-related quality of life

A new study published in PLoS ONE aimed to investigate the effect of using antidepressant medications on the HRQoL of patients with depression.

27 Apr 2022

Talking therapies could be effective for treating depression in people with dementia

Feelings of anxiety and depression are common in people living with dementia and mild cognitive impairment, but the best way to treat these symptoms is currently unknown, as medicines often used to treat these symptoms may not be effective for people with dementia and may cause side effects.

26 Apr 2022

New research provides a scientific framework to allow the use of psilocybin for therapeutic reasons

A new paper by an Oregon State University-led research team provides a scientific framework to help shape the rollout of a program in Oregon that will legally permit the use of psilocybin for therapeutic reasons.

11 Apr 2022

Magic mushroom compound helps to 'open up' depressed people's brains after use

Psilocybin, the psychedelic compound found in magic mushrooms, helps to "open up" depressed people's brains, even after use, enabling brain regions to talk more freely to one another.

11 Apr 2022

Is there a relationship between air pollution and depressive symptoms in adolescents?

In this interview, we speak to Erika Manczak, Ph.D., an Assistant Professor in the Department of Psychology at the University of Denver, about her latest research into the link between air pollution and depressive symptoms in adolescents.

1 Apr 2022

Study shows clinical value of pharmacogenomic testing for patients with treatment-resistant depression

Pharmacogenetic testing was associated with nearly a two-fold (89 per cent) increase in remission rates compared to treatment as usual in a Centre for Addiction and Mental Health- (CAMH-)led clinical study just published in the journal Translational Psychiatry.

29 Mar 2022

Depression occurs independently of inflammation for many older people, study suggests

Multiple prior studies have found higher levels of inflammation in older individuals with depression. Now, a new Penn Medicine study has found that clinically depressed older individuals, on average, don't have elevated levels of inflammation if they don't already have other inflammatory conditions such as arthritis.

28 Mar 2022

Two doses of psilocybin may ease depression symptoms for up to 12 months

Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month.

15 Feb 2022

Treatment rates for major depressive disorder remain low worldwide, analysis reveals

A combined analysis of results from 149 earlier studies finds that treatment rates for major depressive disorder remain low worldwide, particularly for people living in low and lower-middle income countries.

15 Feb 2022

Researchers use embryonic stem cell model to study genetic architecture in the hypothalamus

A study led by researchers at Children's Hospital of Philadelphia has implicated several genes involved in a variety of bodily functions associated with the hypothalamus, a notoriously difficult-to-study region of the brain.

21 Nov 2021

Scientists unravel near-atomic-scale structure of depression-linked brain receptor

Scientists at Scripps Research, Florida have determined the near-atomic-scale structure of an unusual brain-cell receptor called GPR158, which has been linked to depression and anxiety.

20 Nov 2021

One in four adults with ADHD found to have generalized anxiety disorder

A new nationally representative study published online in the Journal of Affective Disorders found that one in four adults aged 20-39 with attention deficit hyperactivity disorder (ADHD) had generalized anxiety disorder (GAD).

18 Nov 2021

Magnus Medical receives FDA's Breakthrough Device Designation for rapid-acting technology to treat major depression

Magnus Medical, Inc., a medical device company, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its individualized, rapid-acting, non-invasive neurostimulation technology designed to treat major depressive disorder (MDD) in people who have not improved sufficiently from antidepressant medication or other treatments.

29 Oct 2021

Major Depressive Disorder News and Research

Further Reading

The effect of antidepressants on patient-reported health-related quality of life

Talking therapies could be effective for treating depression in people with dementia

New research provides a scientific framework to allow the use of psilocybin for therapeutic reasons

Magic mushroom compound helps to 'open up' depressed people's brains after use

Is there a relationship between air pollution and depressive symptoms in adolescents?

Study shows clinical value of pharmacogenomic testing for patients with treatment-resistant depression

Depression occurs independently of inflammation for many older people, study suggests

Two doses of psilocybin may ease depression symptoms for up to 12 months

Treatment rates for major depressive disorder remain low worldwide, analysis reveals

Researchers use embryonic stem cell model to study genetic architecture in the hypothalamus

Scientists unravel near-atomic-scale structure of depression-linked brain receptor

One in four adults with ADHD found to have generalized anxiety disorder

Magnus Medical receives FDA's Breakthrough Device Designation for rapid-acting technology to treat major depression

Study investigates whether continued magnetic seizure therapy can prevent relapse of depression

How has the COVID-19 pandemic affected mental health?

Johns Hopkins Medicine awarded NIH grant to explore the impacts of psilocybin on tobacco addiction

Experts review progress in using photobiomodulation therapy to treat diverse brain disorders

Wrist accelerometer data reveals how sleep is disrupted in mental illness

Study reveals the global impacts of the pandemic on major depressive and anxiety disorders

Study reveals rising rates of depressive and anxiety disorders due to COVID-19 pandemic

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News